| 田华琴,王艳杰,王斌,黄泳立.乳积方对女性乳腺癌术后患者生存状况的影响[J].,2013,33(10):1336-1340 |
| 乳积方对女性乳腺癌术后患者生存状况的影响 |
| Effect of Ruji Recipe on the Post surgical Survival of Female Breast Cancer Patients |
| |
| DOI：10.7661/CJIM.2013.10.1336 |
| 中文关键词: 乳腺癌 乳积方 总生存期 无疾病生存期 生活质量 |
| 英文关键词:breast cancer Ruji Recipe overall survival disease free survival quality of life |
| 基金项目:广东省中医药管理局科研项目课题（No2010002） |
|
| Hits: 2103 |
| Download times: 1406 |
| 中文摘要: |
| 目的 观察乳积方对于女性乳腺癌术后患者预防疾病复发、转移及生活质量的影响。方法 回顾性分析102例手术、化放疗后Ⅰ～Ⅲ期乳腺癌患者，根据是否接受乳积方治疗，分为治疗组和对照组，其中治疗组（54例）接受乳积方治疗，对照组（48例）定期复查，两组中雌激素受体/孕激素受体（ER/PR）阳性患者同时接受内分泌治疗，比较两组总生存期（overall survival，OS）、无疾病生存期（disease free survival，DFS）、复发转移、生活质量情况。结果 100例完成研究随访，中位随访59个月。治疗组和对照组中位OS分别为60.0、52.5个月（χ2=3.274， P>0.05）；中位DFS分别为55.0、47.5个月（χ2=10.145，P<0.01）；两组DFS［75.9%（41/54）、54.3%（25/46）］比较，差异有统计学意义（χ2=－2.259， P<0.05）；2、3、5年DFS比较，差异均有统计学意义（P<0.01）；Ⅱ、Ⅲ期2年DFS及Ⅲ期3年DFS比较，差异均有统计学意义（P<0.05， P<0.01）；ER阳性2、3年DFS比较，差异均有统计学意义（P<0.01，P<0.05）；治疗组3、5年远处转移率（distant metastasis rate，DMR）低于对照组（3.7% vs 31.0%，20.7% vs 60.7%），差异均有统计学意义（P<0.01）。随访结束时，治疗组13例发生疾病进展，局部复发3例、单一脏器转移7例、多个脏器转移3例；对照组21例疾病进展，分别为1、11、9例，差异有统计学意义（P<0.05）。研究开始前1周及随访2年时的生活质量调查比较，治疗组治疗后生活质量较对照组改善明显，差异有统计学意义（P<0.05）。结论 乳积方辅助治疗女性乳腺癌术后患者，2～3年短期时间内，能够改善总生存、无疾病生存、生活质量。 |
| 英文摘要: |
| Objective To observe the effect of Ruji Recipe （RR） in preventing disease recurrence/metastasis and improving quality of life （QOL） for female breast cancer patients after operation. Methods Totally 102 female patients with stage Ⅰ－Ⅲ breast cancer were retrospectively analyzed. They were assigned to the treatment group （54 cases） and the control group （48 cases） according to whether they would rather accept RR therapy. Estrogen receptor/progesterone receptor（ER/PR） positive patients also accepted endocrine therapy. The overall survival （OS）， disease free survival （DFS）， recurrence and metastasis， and QOL were compared between the two groups. Results Totally 100 patients completed the study. The median follow up was 59 months. The median OS was 60 months in the treatment group and 52.5 months in the control group （χ2=3.274， P>0.05）. The median DFS was 55.0 months in the treatment group and 47.5 months in the control group （χ2=10.145， P<0.01）. The DFS rate was 75.9% （41/54） in the treatment group and 54.3% （25/46） in the control group （χ2=－2.259， P<0.05）. There was statistical difference in the 2 ， 3 ， and 5 year DFS between the two groups （P<0.01）. There was statistical difference in the 2 year DFS 3 year DFS between stage Ⅱ and Ⅲ and stage Ⅲ （P<0.05， P<0.01）. There was statistical difference in the ER positive patients between 2 year DFS and 3 year DFS （P<0.01， P<0.05）. There was statistical difference in the 3 and 5 year distant metastasis rate （DMR） in the treatment group， lower than that of the control group （3.7% vs 31.0%，20.7% vs 60.7%； P<0.01）. By the end of follow up， disease progression occurred in 13 cases of the treatment group， local recurrence in 3 cases， single organ metastasis in 7 cases， mutil metastasis in 3 cases， while the corresponding numbers were 21， 1， 11， and 9 in the control group （P<0.05）. As for 1 week before study and at 2 year follow up using Functional Assessment of Cancer Therapy for Breast Cancer （FACT B） system， there was statistical difference in the QOL between the two groups （P<0.05）， and better effect was obtained in the treatment group. Conclusion RR， as an assistant therapy， could improve the OS rate， the DFS rate， and the QOL for post surgical female breast cancer patients in 2－3 years. |
| View Full Text View/Add Comment Download reader |
